Getting Wegovy covered by insurance requires meeting specific clinical criteria, navigating prior authorization, and sometimes appealing a denial. Only 19% of large employers cover GLP-1 medications for weight loss as of 2025, so the path to coverage depends heavily on your insurance type, your medical history, and how your prescriber documents your case.
Who Qualifies Based on FDA Approval
Wegovy is FDA-approved for three groups of people, and your insurance plan will use these categories as a starting point for coverage decisions. The first group includes adults and adolescents aged 12 and older with obesity, defined as a BMI of 30 or higher. The second group is adults with a BMI between 27 and 29.9 who also have at least one weight-related health condition, such as high blood pressure, high cholesterol, or established cardiovascular disease. The third group is adults with established cardiovascular disease (a prior heart attack, prior stroke, or peripheral arterial disease) who have either obesity or overweight. This cardiovascular indication matters a great deal for Medicare coverage, which is discussed below.
Meeting the FDA criteria alone is not enough. Most insurance plans layer additional requirements on top of these thresholds.
What Insurance Plans Typically Require
Prior authorization is almost universal. Among large employers that do cover GLP-1s for weight loss, 80% require it. This means your doctor must submit documentation to the insurer proving you meet specific criteria before the pharmacy will fill the prescription.
Beyond prior authorization, more than half of employer plans (54%) require you to meet clinical criteria stricter than the FDA label. Common extra hurdles include:
- Documented diet and exercise history. Many plans want evidence that you’ve tried a structured lifestyle program, typically for 3 to 12 months, without achieving adequate weight loss. About 28% of covering employers explicitly require participation in a lifestyle program.
- Step therapy. Some plans (13%) require you to try and fail on a cheaper or older weight-loss medication before they’ll approve Wegovy.
- Specialist prescribing. About 13% of plans limit who can prescribe the drug, sometimes requiring an endocrinologist or obesity medicine specialist rather than a primary care doctor.
- Coverage duration limits. Roughly 13% of plans cap coverage at a specific number of refills or a set time period.
The single most important thing you can do is call your insurer before your doctor submits the prior authorization. Ask for the specific criteria on their formulary for Wegovy. This gives you and your prescriber a checklist to build your case around, rather than guessing and getting denied.
How to Build a Strong Prior Authorization
Your prescriber handles the paperwork, but you can improve your odds by making sure your medical record contains the right documentation before they submit. Start by confirming that your chart includes your current BMI, your weight history over the past 6 to 12 months, and a list of your weight-related diagnoses (high blood pressure, high cholesterol, sleep apnea, type 2 diabetes, fatty liver disease, or cardiovascular disease).
If your plan requires proof that lifestyle changes haven’t worked, make sure there’s a record of it. This could be notes from a dietitian, documentation of a medically supervised weight-loss program, or even consistent office visits where your doctor noted dietary counseling. Plans that require step therapy will want records showing you tried another medication and either didn’t lose enough weight or couldn’t tolerate the side effects.
If you have cardiovascular disease, make sure that diagnosis is prominently documented. The cardiovascular indication, based on the SELECT trial showing a 20% reduction in major cardiac events like heart attacks and strokes, is the strongest clinical justification available and opens doors that the weight-loss indication alone does not.
What to Do If You’re Denied
A denial is not the end. Insurance companies count on many people giving up at this stage, but appeals succeed regularly when supported by the right evidence. You typically have two levels of appeal: an internal appeal to the insurer, followed by an external appeal reviewed by an independent physician if the internal appeal fails.
One successful external appeal in New York illustrates what works. The patient documented overweight with dyslipidemia and a liver condition, showed that she had tried diet and exercise for 12 months without success, and demonstrated that she had tried and failed all appropriate alternatives on the plan’s formulary. The independent reviewer cited peer-reviewed studies on semaglutide’s safety and efficacy for obesity, including data from the STEP clinical trial program, and overturned the denial.
For your appeal, ask your doctor to write a letter of medical necessity that includes your specific diagnoses, your BMI, a timeline of prior weight-loss attempts, any medications you’ve tried, and a clear statement explaining why Wegovy is medically appropriate for you specifically. Including references to published clinical trial data strengthens the case, particularly if your plan denied coverage on the grounds that the drug is “not medically necessary.”
Medicare Coverage
Medicare has historically been barred by law from covering drugs prescribed solely for weight loss. That changed partially when the FDA approved Wegovy for cardiovascular risk reduction. After that approval, the Centers for Medicare and Medicaid Services issued guidance confirming that Part D plans can add Wegovy to their formularies for this cardiovascular indication, since it’s no longer classified purely as an anti-obesity drug.
Coverage falls under Part D because Wegovy is a self-administered injection. However, Part D plans are not required to cover every newly approved drug, so coverage varies by plan. If you’re on Medicare and have established cardiovascular disease (prior heart attack, stroke, or peripheral arterial disease) along with a BMI of 27 or higher, check whether your specific Part D plan has added Wegovy to its formulary. If it hasn’t, you may be able to request an exception or switch plans during open enrollment.
If you’re on Medicare but don’t have cardiovascular disease, Wegovy prescribed for weight loss alone remains excluded from coverage by federal law, regardless of your BMI.
Medicaid Coverage
Medicaid coverage for GLP-1 drugs used for obesity varies dramatically by state and has been shrinking. As of January 2026, only 13 state Medicaid programs cover GLP-1s for obesity treatment under fee-for-service. Four states, California, New Hampshire, Pennsylvania, and South Carolina, eliminated coverage in late 2025. North Carolina temporarily dropped coverage due to a budget dispute but reinstated it in December 2025.
States are required to cover Wegovy when it’s prescribed for its cardiovascular indication or for diabetes-related uses, but coverage for weight management alone remains optional. If you’re on Medicaid, contact your state program directly to find out the current status, since coverage decisions are changing frequently.
Manufacturer Savings Programs
Novo Nordisk, the maker of Wegovy, offers a savings program that can reduce your cost to as little as $25 per month for a 28-day supply of the injection. The program is available to people with or without insurance. You can find the savings card on the Wegovy manufacturer website, where you can also check whether your specific insurance plan covers the drug and estimate your out-of-pocket cost.
These savings programs typically have eligibility restrictions and expiration dates that change periodically, so verify the current terms before relying on them as a long-term cost strategy. They also generally exclude government insurance programs like Medicare, Medicaid, and Tricare.
Practical Steps to Maximize Your Chances
Call your insurance plan and request the exact prior authorization criteria for Wegovy in writing. Review your medical records with your doctor to identify any gaps in documentation, particularly around BMI history, prior weight-loss efforts, and diagnosed comorbidities. If you have cardiovascular disease, make sure your prescriber highlights the cardiovascular indication rather than framing the prescription as weight management alone.
If your employer plan doesn’t cover Wegovy at all, check whether your benefits include any carve-out programs for weight management or chronic disease. Some employers contract with specialty vendors that manage GLP-1 access separately from the main pharmacy benefit. If your plan explicitly excludes all anti-obesity medications, your options are limited to the manufacturer savings program, switching plans during open enrollment, or asking your employer’s HR department whether coverage changes are being considered. With the landscape shifting rapidly, plans that excluded GLP-1s last year may add them this year.